Inhibikase Therapeutics
IKT
5 hedge funds and large institutions have $936K invested in Inhibikase Therapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.22% more ownership
Funds ownership: 0% → 0.22% (+0.22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$845K |
| 2 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$159K |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
+$92.9K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$42.2K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$2.13K |
Top Sellers
IKT Hedge Fund Activity: Q4 2020 in Review
5 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2020, worth a combined $936K.
Buyers outnumbered sellers: 5 funds opened new IKT positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $845K.
- 5 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $936K of Inhibikase Therapeutics stock for Q4 2020.
- 5 funds opened new Inhibikase Therapeutics positions in Q4 2020 and 0 closed out, a net change of +5 holders.
- The largest Inhibikase Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $845K added.
Based on aggregated 13F filings for Q4 2020.